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Abstract 
A high-dose local tranexamic acid has been
introduced in total knee arthroplasty for bleed-
ing control. We are not sure about the systemic
absorption and side effects. The aim of this
study was to evaluate the effect of low dosage
of  intra-articular  tranexamic  acid  injection
combined with 2-hour clamp drain in minimal-
ly  bleeding  computer-assisted  surgery  total
knee  replacement  (CAS-TKR).  A  prospective
randomized controlled trial was conducted in a
total of 48 patients underwent CAS-TKR. The
patients  were  randomly  assigned  to  receive
either  of  a  mixed  intra-articular  solution  of
tranexamic  acid  250  mg  with  physiologic
saline (TXA group), or physiologic saline (con-
trol group) and then followed by clamp drain
for 2 hours. Postoperative blood loss was meas-
ured by three different methods as drainage
volume, total hemoglobin loss and calculated
total blood loss. Transfusion requirement and
postoperative complications were recorded. All
patients were screened for deep vein thrombo-
sis and the functional outcomes were evaluat-
ed at 6 months after surgery. The mean postop-
erative drainage volume, total hemoglobin loss
and calculated total blood loss in TXA group
were 308.8 mL, 2.1 g/dL and 206.3 mL com-
pared to 529.0 mL, 3.0 g/dL and 385.1 mL in the
control group (P=0.0003, 0.0005 and <0.0001
respectively). Allogenic blood transfusion was
needed for one patient (4.2%) in TXA group
and for eight patients (33.3%) in the control
group. Postoperative knee scores were not sig-
nificantly different between groups. No deep
vein thrombosis, infection or wound complica-
tion was detected in both groups. In this study,
low dose intra-articular tranexamic acid injec-
tion combined with 2-hour clamping drain was
effective for reducing postoperative blood loss
and  transfusion  requirement  in  CAS-TKR
without significant difference in postoperative
complications or functional outcomes. 
Introduction 
Transfusion of allogeneic blood components
is the major concern in many surgical special-
ists due to the risk of transfusion-related mor-
bidity;  for  instance  viral  infections,  transfu-
sion-related  acute  lung  injury  (TRALI),
hemolytic transfusion reactions (HTRs), and
transfusion-associated  sepsis  (TAS).1 In
orthopaedics, total knee replacement (TKR) is
major  surgery  in  which  associates  to  large
amount of blood loss and blood transfusions
may be required in particular patients. Even
with  computer-assisted  surgery  total  knee
replacement  (CAS-TKR)  procedure  that,  by
theoretically,  should  be  reduced  blood  loss
because intramedullary femoral guide was not
necessary,2 however,  in  our  experience,  we
found that blood loss was high up to 1320 mL
and require transfusion as 0.41 unit/patient.
Tranexamic acid (TXA), an anti-fibrinolytic
agent, has been demonstrated the efficacy to
reduce  perioperative  blood  loss  and  transfu-
sions in orthopaedic surgery.3 In TKR, results
from  meta-analysis  confirmed  that  intra-
venous tranexamic acid (IV-TXA) application
significantly reduce perioperative blood loss by
40-50% and proportion of the patients requir-
ing blood transfusion to about 10% when com-
pared to placebo.4 However, disadvantages of
IV-TXA  method  are  prolonged  high  systemic
drug level from multiple injections or continu-
ous infusion, and leading to drug-induced sys-
temic thromboembolic events.5
Recently,  intra-articular  tranexamic  acid
(IA-TXA)  application  in  TKR  was  introduced
and  has  been  proved  to  significantly  reduce
postoperative blood loss and knee swelling.6, 7
However, through our knowledge, the protocol
for  the  IA-TXA  application,  regarding  to  the
dosage, the need of non-using drain or clamp
drain  technique,  is  still  not  established.
Moreover, the amount of TXA used in previous
studies was high as 2000-3000 mg. Nilsson et
al. reported that the plasma concentration of
TXA only of 10 mg/L was appropriated for anti-
fibrinolytic action8 which was correlated to the
concentration 10-20 mg/mL in the topical TXA
solution in that had been proved in previous
clinical  studies.9-11 Additionally,  Kiely  et  al.
reported that the drains could be clamped for 2
h without compromising the final clinical out-
comes.12 Therefore, we hypothesized that the
concentration  of  IA-TXA  solution  only  10
mg/mL  combined  with  2-hour  clamp  drain
should be or may be sufficient to reduce post-
operative blood loss and transfusion require-
ment. The objective of this randomized study
was to evaluate the effect of a very low concen-
tration of IA-TXA solution for reducing blood
loss and transfusion in CAS-TKR.
Materials and Methods 
Participants, inclusion/exclusion
criteria, randomization
This was a single-center prospective, non-
stratified,  triple-blinded,  randomized  study
with 1:1 allocation ratio and prior approval was
obtained from our institutional review board.
Informed  consent  was  obtained  from  all
patients who participated in this study, before
the surgery was scheduled, in accordance with
the Declaration of Helsinki. The manuscript
was  prepared  according  to  the  Consolidated
Standards  of  Reporting  Trials  (CONSORT)
2010 guideline.13
Eligible  participants  were  patients  diag-
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nosed  as  primary  knee  osteoarthritis  and
underwent unilateral primary cemented CAS-
TKR  between  September  2008  and  October
2009. The inclusion criteria were i) no previ-
ous  knee  surgery;  ii)  no  risk  of  abnormal
bleeding tendency or bleeding disorder (nor-
mal  coagulogram,  serum  creatinine  <2.0
mg/dL,  stop  nonsteroidal  anti-inflammatory
drugs and antiplatelet drugs more than 7 days;
and iii) no contra-indication for TXA use (no
active  intravascular  clotting  process,  no
acquired defective colour vision, no subarach-
noid hemorrhage, no hypersensitivity to TXA,
and  no  any  of  history  of  serious  adverse
effects, thrombotic disorder and hematuria).
The exclusion criteria were those with incom-
plete  data  collection,  for  example,  malfunc-
tioned drain or accidental drain removal. 
The  blocked-randomization  was  generated
by STATA 11.0 software (Stata Corp, College
Station, Texas, USA), with block size of four,
and further concealed with sealed envelopes in
the  sequentially  numbered  container.  The
envelopes  were  sequentially  opened  intra-
operatively  after  fascial  closure  by  research
assistant  that  did  not  involved  in  outcome
assessment. Then all patients were allocated to
one of two groups; TXA group or control group
(Figure 1). 
Drug preparation and
administration method
In both the TXA and control group, the solu-
tion  was  prepared  by  research  assistant  as
total 25 mL volume in the same-size syringe,
according to allocation received, under sterile
condition and behind the fluoroscopic scene in
order to blind surgeon and outcome assessor.
The solution was injected to knee joint after
completion of fascial closure in order to pre-
vent leakage. In TXA group, the solution con-
tained 250 mg of tranexamic acid in 5 mL vol-
ume  (Transmin®,  OLIC  (Thailand)  Limited,
Ayutthaya, Thailand), and 20 mL of physiologic
saline. In the control group, the solution was
only 25 mL of physiologic saline. Both prepared
solution had same appearance.
Data collection
Demographic  data  such  as  age,  gender,
height,  weight,  underlying  disease,  side  of
operation,  American  Society  of
Anesthesiologists (ASA) physical status, pre-
operative  hemoglobin  and  hematocrit  were
collected preoperatively, by research assistant,
and  then  further  calculated  into  body  mass
index  (BMI)  and  estimated  blood  volume
(EBV).14,15 Radiographic osteoarthritis grading
was  assessed  preoperatively  by  two
orthopaedic  surgeons,  according  to  Ahlbäck
classification.16 Baseline knee function score,
as  Knee  Society  Knee  score  and  Western
Ontario  and  McMaster  Universities
Osteoarthritis  Index  (WOMAC)  were
obtained.17,18
Surgical procedure and
postoperative care
Surgery  was  performed  by  one  of  the
authors,  who  was  experienced  CAS-TKR
arthroplasty  surgeon.  The  decision  on  anes-
thetic technique, general or regional anesthe-
sia,  was  depended  on  the  anesthesiologists
who did not involve in this study. All patients
were performed CAS-TKRs by using a medial
parapatellar approach with midvastus incision
under  pneumatic  tourniquet  with  pressure
100-150 mmHg above systolic blood pressure.
The  Ci  knee  essential  version  2.0  software
(DePuy/Brainlab, Feldkirchen, Germany) was
used in this study. The prostheses used in this
study  were  LCS  or  PFC  sigma  knee  system
(Depuy,  Warsaw,  IN,  USA)  depended  on  the
patient’s selection before the surgery. All pros-
thesis  inserted  with  full  cementation
(Palacos®, Hevaeus Medical GmbH, Germany).
A standard drain tube (size 8 Redon drain, B-
Braun Ltd.) was placed deep into knee joint,
exited superolaterally, and connected to high-
pressure  vacuum  drain  (Drainobag® 600V
Lock, B-Braun, Melsungen AG, Germany). No
superficial drain was used in this study. After
fascia closure, the prepared sterile solution in
25-mL syringe, either placebo or TXA solution,
was sent to the surgeon and then injected into
knee joint. Subcutaneous and skin closure was
performed  subsequently.  Bulky  compressive
dressing  was  applied  before  tourniquet  was
deflated. The drain was clamped for 2 h before
fully  opened.  Intra-operative  data,  such  as
anesthetic technique, operative time, incision
size, prosthesis design and patella resurfacing
selection were recorded.
Drain  and  compressive  dressing  were
removed at 48 h postoperatively. During this
period, the patients were encouraged to have
active  ankle  motion  to  prevent  deep  vein
thrombosis (DVT). The patients were advised
to move the legs and then trained to walk with
gait aid after removal of compressive dressing
on the second postoperative day. All patients
were sent for duplex doppler ultrasound on the
fourth postoperative day. 
Outcome measurement method
Basic postoperative data, such as drain vol-
ume,  hematocrit  (Hct),  hemoglobin  (Hb),
amount  of  blood  transfusion,  and  WOMAC
score, were collected by well-trained research
assistant.  Complicated  postoperative  data
requiring  clinical  examination  or  physician
diagnosis, such as range of motion, and diag-
nosis of complication, were collected by one of
the authors who was experienced orthopaedic
surgeon.  Both  of  them  were  blinded  to  the
treatment  allocation.  Drain  volume  was
recorded  cumulatively  at  1-hour  interval  for
first two hours, then 2-hour interval for the
next 10 h, followed by 4-hour interval for 12 h
and 12-hour interval for one day after clamp
release (Figure 2). After the patient was trans-
fer to ward, on first postoperative day, Hct was
measured immediately, at the fourth hour and
every 8 h subsequently. Then Hct was meas-
ured every 12 h on second postoperative day
and  followed  by  once  daily  until  the  fourth
postoperative day. Whenever Hct level was less
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Figure 1. Flow diagram of this study. CAS-TKR, computer-assisted surgery total knee
replacement; TXA, tranexamic acid.[Orthopedic Reviews 2011; 3:e12] [page 53]
than 25%, Hb was measured in order to evalu-
ate the need of transfusion. Blood transfusion
was considered, according to ASA guideline,
when Hb was less than 8 gm% or the patient
had  positive  anemic  symptom  (dyspnea,
tachypnea  and  hypoxemia).19 On  the  fourth
postoperative day, Hb was measured in order to
calculate for blood loss.
Postoperative blood loss was measured in
three different methods: drainage blood loss
(DBL), total Hb loss (THL) and calculated total
blood loss (CTBL). THL and CTBL were calcu-
lated by using specific formulation.15, 20 DBL in
each time interval was further calculated into
drainage blood loss rate (DBLR) defined by fol-
lowing formula.
DBLR (mL/hour) = Drain volume in
time interval (mL) / No. of hour in
time interval (hour)
Blood  transfusion  requirement  was  meas-
ured by the number of patients receiving trans-
fusion and amount of transfusion unit.
Functional outcomes, such as Knee Society
Knee score and WOMAC score, were evaluated
at the clinic at 3-month and 6-month period
postoperatively.  Postoperative  complications
such as wound hematoma, surgical site infec-
tion or systemic infection were evaluated at
ward, at clinic as time of follow-up and/or by
phone interview periodically. 
Sample size calculation
Sample  size  was  estimated  by  using  the
Power & Sample size (PS) calculation software
version 3.0.0002 (Vanderbuilt) and data review
of patients who were primary osteoarthritis of
knee and underwent primary CAS-TKR from
2007-2008 (mean drainage volume = 715 mL,
standard deviation = ± 277.25 mL). Assuming
the effect of blood loss reduction should more
than 35% (δ= 184 mL) with pre-study power of
test (β) was set as 0.8 and significant differ-
ence  (α)  as  0.05,  the  sample  size  of  each
group was 20 patients. Then 20% withdrawal
rate  (4  patients)  was  added.  Therefore,  the
sample size was 24 patients for each group.
Statistical analysis
Statistical  analysis  was  performed  using
Stata  software  version  11.0  (Stata  Corp,
College  Station,  Texas,  USA).  Intention-to-
treat analysis was applied. Normailty of data
was  tested  by  Kolmogorov-Smirnov  test.
Continuous data were presented as mean and
standard  deviation,  and  compared  with
unpaired t-test. Categorical data were present-
ed  as  proportion  and  compared  with  Chi-
square test. Relative risk with 95% confidence
interval  (C.I.)  was  estimated  for  the  risk  of
having  blood  transfusion  between  groups.
Significant  difference  was  considered  if
P<0.05.
Results 
Demographic data and
intra-operative data
From  September  2008  to  October  2009,
there  were  54  patients  that  underwent  pri-
mary  cemented  unilateral  CAS-TKR  in  this
study. Six patients were excluded that includ-
ing refusal to participate (4 patients), serum
creatinine more than 2.0 mg% (1 patient) and
abnormal coagulogram (1 patient). A total of
48 patients (40 females and 8 males) were
recruited  and  randomly  assigned  into  2
groups; i) control group and ii) TXA group. All
patients  in  both  groups  were  followed  our
postoperative protocol and completed follow-
up  at  6-month  period  (Figure  1).  Forty
patients were female and eight of them were
male. The mean age of all patients was 69.1
years (range 52-83 years). The mean BMI and
preoperative  hemoglobin  were  26.9  kg/m2
(range 21.1-35.2 kg/m2) and 12.3 g/dL (range
10.3-15.7 g/dL). The mean operative time was
119.6 min. (range 90-165 min.). There were
no differences in the age, gender, BMI, EBV,
ASA physical status, side of operation, radio-
logic osteoarthritis grading, preoperative Hb
level  and  preoperative  functional  score
between both groups. However, more patients
in the TXA group had the ASA class III com-
pared with the control group (Table 1). The
anesthetic  technique,  operative  time,  pros-
thesis type, patella resurfacing selection and
incision  size  also  no  significant  difference
between both groups (Table 2).
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Figure 2. Illustration depicting mean accumulated drainage blood loss in TXA group and
control group at each recorded time after clamp release. Significant differences between
the  groups  were  seen  in  all  the  recorded  time  48  h  postoperatively.  (*P<0.0001,
**P<0.00001).
Table 1. Baseline demographic data in both groups.
Demographic data TXA group Control group
(n=24) (n=24) P
Age* (year) 69.0 (8.2) 69.2 (7.6) 0.942°
Female gender (%) 22 (91.7) 18 (75) 0.245**
BMI* (kg/m2) 27.0 (3.4) 26.8 (4.1) 0.891°
EBV (mL), (range) 3103.2 (2920.2-3897.3) 3240.4 (2920.2-4434.5) 0.205°
ASA physical status (II/III) 10 / 14 13 / 11 0.564**
Side of operation (Right) (%) 11 (45.8) 11 (45.8) 1.000**
Radiographic osteoarthritis grading (3/4/5) 4 / 11 / 9 3 / 9 / 12 0.680**
Pre-operative hemoglobin† (g/dL) 12.2 (1.1) 12.5 (1.3) 0.419°
Pre-operative knee society score* 77.3 (20.2) 78.3 (16.3) 0.845°
Pre-operative WOMAC score* 52.5 (14.8) 54.5 (15.7) 0.653°
*The values were presented as mean (standard deviation); °P based on unpaired t-test; **P based on Fisher’s Exact test.
BMI, body mass index; EBV, estimated blood volume; ASA, American Society of Anesthesiologists[page 54] [Orthopedic Reviews 2011; 3:e12]
Blood loss and transfusion
requirement
Blood loss in TXA group was significantly
lower than that in control group in all meas-
urement methods (DBL, THL, and CTBL) as
shown in Table 3. Blood transfusion require-
ment  in  TXA  group  was  also  significantly
lower than the control group with relative risk
as 0.13 (95% confidence interval: 0.02-0.92).
Accumulated drainage volume in TXA group
was significantly lower than that in control
group  all  the  recorded  time  after  clamp
release (Figure 2). DBLR in TXA group was
also significantly lower than that of control
group  in  the  first  6  hours  after  release  a
clamp (Figure 3).
Complications and
postoperative knee function
No any complication (deep vein thrombosis,
infection and wound complication) was found
in our present study. No significant difference
in  postoperative  knee  function  scores  at  3-
month and 6-month periods between groups
(Table 4).
Discussion 
Tranexamic acid (TXA) is an anti-fibrinolyt-
ic agent in which helps to decrease blood loss
by inhibition of clot degradation through com-
petitive  inhibitor  of  plasminogen  activation
mechanism.3 The  result  from  recent  studies
demonstrated  the  advantage  of  the  IA-TXA
application to reduce postoperative blood loss
and knee swelling associated with the TKR.6,7
In  this  prospective  randomized  controlled
study, we developed a new method, for decreas-
ing blood loss in CAS-TKR, which combined
low dose IA-TXA injection with 2-hour drain
clamping and evaluated its efficacy and safety.
The use of IA-TXA injection has many theo-
retically  and  practically  advantages.  First,
local activation of thrombosis and fibrinolysis
started  during  and  after  surgery  while  sys-
temic activation of those started when local
mediators from the injured limb are released
after  tourniquet  deflation.21 Therefore  the
local  (intra-articular)  and  intra-operative
application  of  TXA  would  be  more  specific
method than systemic (intra-venous) route.
Second, in vitro studies, TXA showed the abil-
ity to increase thrombus formation as dose-
dependent action and reduce time to occlu-
sion  when  compared  to  control  group.22,23
Thus, using only small amount of TXA in lim-
ited knee joint volume to create the high TXA
concentration inside knee joint should result
Article
Figure 3. Illustration depicting mean drainage blood loss rate in TXA group and control
group  at  each  recorded  time  after  clamp  release.  Significant  differences  between  the
groups were seen only in the first 6 hours postoperatively. (*P<0.05, **P<0.001).
Table 2. Operative details in both groups.
Operative data TXA group Control group
(n=24) (n=24) P
Regional anesthesia (%) 23 (95.8) 21 (87.5) 0.609**
Operative time* (minute) 115.5 (16.2) 123.7 (23.3) 0.166°
Prosthesis (LCS/PFC sigma) 19 / 5 19 / 5 1.276**
Patellar resurfacing (%) 14 (58.3) 13 (54.2) 0.771**
Incision size* (cm) 11.9 (0.9) 11.9 (0.8) 0.999°
*Values presented as mean (standard deviation);°P calculated by using unpaired t-test; **P calculated by using Fisher’s Exact test. 
Table 3. Blood loss and blood transfusion outcome in both groups.
Blood loss outcome variables TXA group Control group
(n=24) (n=24) P
Drainage blood loss* (mL) 308.8 (185.0) 529.0 (206.4) 0.0003°
Total Hb loss* (g/dL) 2.1 (0.9) 3.0 (0.7) 0.0005°
Calculated total blood loss* (mL) 206.3 (115.4) 385.1 (145.2) <0.0001°
Blood transfusion use (no. of patients) (%)  1 (4.2) 8 (33.3) 0.023**
*Values presented as mean (standard deviation); °P value calculated by using unpaired t-test; ++P calculated by using Fisher’s Exact test. 
Table 4. Results of functional outcomes.
Functional outcome variables TXA group Control group
(n=24) (n=24) P
Knee Society Knee Score*
3 months 127.7 (16.6) 123.3 (15.5) 0.342°
6 months 147.3 (10.7) 146.9 (10.5) 0.892°
WOMAC score*
3 months 29.8 (7.9) 32.1 (10.5) 0.399°
6 months 18.6 (7.6) 20.8 (6.4) 0.282°
*Values presented as mean (standard deviation); °P calculated by using unpaired t-test.[Orthopedic Reviews 2011; 3:e12] [page 55]
in  greater  thrombus  formation  and  shorter
time to occlusion compared to lower tissue
level  after  drug  distribution  from  IV-TXA
injection. Third, animal study showed topical
delivery of TXA had very low systemic absorp-
tion.24 Hence,  systemic  absorption  after  IA-
TXA  method  combined  with  delayed  drain
release should be lower than those after IV-
TXA  method  resulting  in  avoiding  systemic
side effect. And fourth, IA-TXA method was
simple, inexpensive and easy to perform (The
cost of TXA 1 ampule in our country was about
1 $).
Previous studies supported the use of TXA
as intra-articular agent.6,7,25 In 1997, Akizuki
et  al. used  a  method  combined  multiple
haemostatic agent, including fibrin glue, car-
bazochrome sodium sulfonate and TXA, and
30-min. clamp drain in the patients under-
went  primary  cementless  TKR.25 None  of
patients  required  blood  transfusion.
However,  this  study  was  case  series  study
and the pure effect of IA-TXA has not been
demonstrated.
Wong et al., in 2010, compared two topical
TXA  solutions  with  different  concentration,
containing 1.5 g and 3.0 g of TXA in 100 mL of
physiologic saline (150 and 300 mg/mL), with
a placebo solution in the patients underwent
primary TKR. The solution was applied to the
open joint surfaces and left in contact with
tissue for five min., and then surgical wound
was closed without using drain.6 The results
showed that topical TXA application reduced
postoperative bleeding by 20-25% and result-
ed in 16-17% higher postoperative Hb values
without increasing thromboembolic or other
complications.  Nevertheless,  the  authors
found  that  plasma  TXA  concentration,  one
hour after tourniquet release, was above than
minimum therapeutic concentration and con-
cluded that the effect of their method may be
secondary to systemic absorption.
Ishida  et  al.,  in  2011,  compared  IA-TXA
injection, containing 2.0 g of TXA in 20 mL
(100 mg/mL), with a placebo solution in the
patients underwent primary TKR.7 After injec-
tion, the drain was clamped for 30 min and
followed  by  gradual  release  protocol.  The
results showed IA-TXA injection could reduce
postoperative blood loss, by decrease in Hb
reduction, and knee joint swelling. However,
the authors concluded that, in their study, the
total amount of TXA used was not low dose
and the true incidence of DVT was not identi-
fied due to lack of methods detecting clinical-
ly asymptomatic DVT (such as ultrasound or
venography).
The preparation of IA-TXA solution in our
study was TXA 250 mg in the 25-mL physiolog-
ic saline that equivalent to the concentration
of  10  mg/mL.  This  concentration  has  been
used in routine cardiothoracic surgery.9-11 The
25 mL volume of solution was the amount of
solution contained inside the knee joint with-
out leakage. 2-hour clamp drain was append-
ed, to maintain intra-articular drug concen-
tration for allowing sufficient time to create
anti-fibrinolytic  action  from  topical  applica-
tion and should also prevent immediate brisk
blood loss resulted by increased in the initial
blood flow and created temponade effect after
tourniquet  release  without  excess  morbidi-
ty.12,26
According to the results of this study, TXA
group showed the ability to reduce postopera-
tive blood loss and blood transfusion require-
ment. The decreasing blood loss effect was as
42% of drainage blood loss (P=0.0003), 30%
of total Hb loss (P=0.0005), and 46% of calcu-
lated total blood loss (P<0.0001). When com-
pared  to  control  group,  proportion  of  the
patients requiring blood transfusion was sig-
nificantly  reduced  to  only  12.5%  (absolute
risk  reduction  of  transfusion  requirement
was 29.1% and number needed to treat (NNT)
was 3.42). 
Concerning of any potential factors might
affect on perioperative blood loss, subgroup
analysis was performed in patients received
regional anesthesia and LCS prosthesis. The
results were consistent with those seen in all
patients’  analysis.  In  the  patients  received
regional anesthesia, the mean DBL, THL and
CTBL in TXA group (n=23) were 302.6 mL, 2.1
g/dL and 195.5 mL compared to 537.9 mL, 3.0
g/dL  and  377.8  mL  in  the  control  group
(n=21)  (P=0.0004,  0.0006  and  <0.0001
respectively).  In  the  patients  received  LCS
prosthesis, the mean DBL, THL and CTBL in
TXA group (n=19) were 292.6 mL 2.1 g/dL and
201.1 mL compared to 536.8 mL, 3.0 g/dL and
383.0  mL  in  the  control  group  (n=19)
(P=0.0003, 0.0034 and <0.0001 respectively).
Moreover,  according  to  systematic  review,
Macfarlane et al found no difference in peri-
operative blood loss in patients received gen-
eral anesthesia versus regional anesthesia.27
Additionally, there is still no clear evidence
showed  the  effect  of  prosthesis  design  or
patella  resurfacing  on  perioperative  blood
loss.  However,  with  the  randomization,  the
effect  of  these  factors  would  be  controlled
equally in each study group.
Our  findings  of  reducing  postoperative
blood loss are consistent with the findings of
previous  studies  of  IA-TXA  application  in
patients underwent TKR.6,7,25 Additionally, this
present  study  has  been  demonstrated  the
effectiveness of the combined IA-TXA injec-
tion with 2-hours clamp drain method in the
aspect  of  decreasing  postoperative  transfu-
sion requirement. Our study are also compa-
rable with the results of previous meta-analy-
ses  of  the  IV-TXA  application  in  patients
underwent TKR which demonstrated a reduc-
tion of proportion of patients requiring blood
transfusion  (summary  odds  ratio  0.10,  95%
confidence  interval  0.06-0.18:  P<0.00001)
when compared with patients who received
placebo.4 Furthermore, the amount of TXA use
in our intra-articular method was much less
than those in previous studies (at least 6 to
12 times).4,6,7 Because of this very low TXA
amount use and expected very low systemic
absorption  in  intra-articular  application,
therefore it could be implied that the thera-
peutic effect of IA-TXA in our study should be
local effect in surgical wound. 
Although  clamp  drain  had  theoretical
advantages as prevention of immediate blood
loss and promoting blood clot formation from
temponade  effect,  but  the  results  of  clamp
drain  were  controversial  among  literature.
One previous study in CAS-TKR with 1-hour
clamp drain found no significant difference in
drainage  blood  loss  while  another  study  in
conventional  TKR  with  1-hour  clamp  drain
found significant reduced postoperative blood
loss and transfusion requirement.28,29 Thus, it
implies that IA-TXA method should add on the
clamp drain effect in TXA group to increase
thrombus  formation  and  prolong  clot  lysis
resulting  in  less  total  blood  loss  and  blood
transfusion when compared to control group
which had only clamp drain effect. Moreover,
this add-on effect should also be temporary
effect, explained by a significant DBLR reduc-
tion in TXA group in only first 6 h (Figure 3).
Our findings of thromboembolic or wound
complication and postoperative knee function
were comparable with those in previous IA-
TXA study.6 This very low incidence of throm-
boembolic manifestation, detected by duplex
doppler ultrasound, may be explained by small
population  size  and  the  decreasing  emboli
effect related to CAS-TKR.3
The  present  study  had  some  limitations.
First,  the  study  population  was  limited  to
patients underwent CAS-TKR, therefore the
result might be different with conventional
TKR. Second, though there was shown posi-
tive  result  for  decreasing  blood  loss  and
transfusion requirement but it needed more
study population to find any possible compli-
cation.
In conclusion, low dose IA-TXA injection, as
only 250 mg of TXA, combined with 2-hour
clamp drain in patients undergoing CAS-TKR
was one interesting option in reducing post-
operative blood loss by 40-46% and proportion
of patients requiring blood transfusion to 13%
as compared to placebo. Its application was
simple,  inexpensive,  easy  to  perform,  and
effective as compared to previous IA-TXA or
IV-TXA method without any significant throm-
boembolic or other complications. The further
research was required for the effectiveness in
conventional total knee replacement.
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